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Unprecedented advancements in interventional techniques
and the advent of new drug-eluting stents coupled with
refinements in adjuvant antithrombotic strategies have led
to significant improvement in acute procedural success and
long-term clinical outcomes after percutaneous coronary
interventions (PCI) (1). Currently, PCI remains the most
frequent form of coronary revascularization, including com-
plex patients presenting significant clinical and anatomic
challenges (1). However, myocardial injury is frequently
induced during PCI (2). In particular, brief episodes of
transient coronary flow deterioration or distal microemboliza-
See page 2048
tion of particulated atherothrombotic debris (at the main
vessel or its side branches) may be associated with micro-
vascular injury and myocardial inflammation with subse-
quent increase in cardiac markers (2). This problem—
occurring in “angiographically successful” PCI—is more
evident in patients undergoing complex and prolonged
procedures, particularly when multiple lesions are treated
(1,2). Nowadays, the use of very sensitive cardiac markers
enables the identification of even subtle degrees of myocar-
dial damage that otherwise would remain clinically unrec-
ognized. The prognostic implications of such troponin
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universal definition of myocardial infarction recommended
that the diagnosis of procedure-related myocardial infarc-
tion (type 4a) requires a clear increase (5 times normal
values) in cardiac troponin levels together with objective
signs of ischemia (2). Instead, the term myocardial injury
should be used in patients with lower troponin levels.
Notably, type 4a myocardial infarction, regardless of size, is
associated with an increased long-term risk of cardiovascular
death, which can be mitigated with the use of more potent
antiplatelet treatment regimens (3,4). The availability of
these uniquely sensitive and specific biomarkers of cardiac
injury also represents a new opportunity to further scrutinize
the potential clinical value of several new adjuvant pharma-
cological therapies aimed to optimize the results of coronary
revascularization. In this regard, drugs able to reduce the
extent of myocardial injury at an “analytical level” may then
gain further promise and eventually emerge as primetime
strategies to effectively reduce episodes of clinically relevant
myonecrosis and, more importantly, improve long-term
prognosis.
Patients with non–ST-segment elevation myocardial in-
farction (NSTEMI) represent a particularly high-risk clin-
ical subset of patients who require aggressive medical
management and coronary revascularization when the anat-
omy is suitable (1–4). By definition, these patients have
already had some degree of myocardial necrosis. In this
scenario, both systemic and local inflammation, together
with an enhanced thrombogenic milieu, provide a uniquely
challenging underlying pathophysiological substrate. Clini-
cal investigations have shown that NSTEMI patients
treated with more potent antiplatelet therapies have im-
proved short- and long-term outcomes (5). More recently,
the value of acute statin therapy in these patients has also
been suggested (6). Several studies have advocated that
statins provide clear-cut clinical benefit in patients under-
going PCI likely through their “pleiotropic” properties (7,8).
These appear to modulate both inflammatory and platelet-
mediated processes, which are strongly interrelated and both
key in atherogenesis and its thrombotic complications (9).
herefore, further research efforts focused on novel thera-
eutic targets linking systemic and local inflammation with
latelet aggregation and thrombus formation are welcome.
ationale for targeting P-selectin. Recruitment of leuko-
ytes, such as monocytes, lymphocytes, and neutrophils, to
he arterial vessel wall is the first step in the development of
therosclerosis (9,10). In particular, leukocyte homing in
his process occurs through a dynamic adhesion cascade,
hich includes tethering (or capture), rolling, adhesion, and
ransmigration. Selectins and their ligands mediate the
ethering and rolling phases (11). Various selectins and
igands have been described, of which P-selectin and its
igand P-selectin ligand-1 (PSGL-1) are the best character-
zed. P-selectin is calcium-dependent protein stored in the
lpha and dense granules of platelets and in the Weibel-
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activation, P-selectin is rapidly translocated to the surface of
these cells. In addition to being expressed on the platelet
membrane surface, P-selectin is soluble in the bloodstream.
Cell surface–bound and soluble P-selectin can be measured by
flow cytometry and enzyme-linked immunosorbent assay
techniques, respectively. P-selectin expression on the plate-
let membrane has been considered a marker of platelet
activation and a measure of the pharmacodynamics efficacy
of antiplatelet drugs, whereas soluble P-selectin has been
studied as a marker of cardiovascular risk (12,13).
P-selectin is a key mediator in platelet-leukocyte and
leukocyte-endothelium interactions and has an important
role in the interplay between inflammation and platelets in
atherogenesis and its thrombotic complications (Fig. 1)
(9–12). These interactions are mediated through the bind-
ing of P-selectin to PSGL-1 present on the leukocyte
surface (11,12). Tethering is the first step of leukocyte
adhesion, which decelerates the fast-flowing leukocytes
from the circulation (“braking system”) and allows them to
interact (“rolling”) with the activated endothelium (11,12).
Rolling leukocytes then activate downstream adhesion mol-
ecules, such as vascular cell adhesion molecule and others
Figure 1 Role of P-Selectin Linking Inflammatory and Thrombot
P-selectin is stored in the alpha and dense granules of platelets and in the Weibe
rapidly translocated to the surface of these cells as well as released soluble into
interactions and has an important role in atherothrombosis. Recruitment of leukoc
sclerosis, which occurs through a dynamic adhesion cascade, which includes teth
mediate the tethering and rolling phases, which occur through the binding of P-sel
first step of leukocyte adhesion, which decelerates the fast-flowing leukocytes from
vated endothelium. Rolling leukocytes then activate downstream adhesion molecu
endothelium followed by cell transmigration. Binding of P-selectin to PSGL-1 also p
vated endothelial cells mediates platelet rolling. This process decelerates platelet
Binding of P-selectin to the PSGL-1 on leukocytes also favors the release of proco
sition, and stabilization of the thrombus.expressed on the activated endothelial cells, which allow
firm adhesion to the endothelium followed by transmigra-
tion. In addition to mediating the above-mentioned cell-cell
interaction, P-selectin is also responsible for further activa-
tion of the endothelium, creating a positive feedback mech-
anism (11,12). Binding of P-selectin to PSGL-1 also
participates in the regulation of vascular thrombosis (14). In
fact, P-selectin expressed on activated endothelial cells
mediates platelet rolling, which may decelerate platelets at
the site of vascular injury and contribute to the development
of a platelet plug. P-selectin can be shed from activated
platelets or endothelial cells in a soluble form or as part of
microparticles. Binding of P-selectin to PSGL-1 on leuko-
cytes also favors the release of procoagulant microparticles
and tissue factor. Tissue factor not only activates the
coagulation cascade but can also mediate inflammatory
responses. P-selectin expressed on the activated platelets in
thrombi favors the recruitment of procoagulant micropar-
ticles to the thrombus by binding of PSGL-1 on micropar-
ticles (14). Overall, these processes favor thrombin generation,
fibrin deposition, and stabilization of the thrombus (9–14).
P-selectin is important not only in spontaneously occurring
atherothrombotic complications, but also iatrogenic vascular
thophysiological Pathways at the Arterial Vessel Wall
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Targeting P-Selectin During Coronary Interventions May 21, 2013:2056–9injury as in the setting of PCI. Animal studies showed that
antagonism of P-selectin diminishes inflammatory and
thrombotic responses elicited by PCI, and P-selectin antag-
onism has been associated with a reduction of neointimal
hyperplasia after PCI (15). Importantly, P-selectin antago-
nism reduces the presence of inflammatory mediators in-
cluding macrophage infiltration as well as proinflammatory
cytokines such as tumor necrosis factor alpha and
interleukin-1 known to trigger neointimal hyperplasia
fter vascular injury. Ultimately, P-selectin antagonism also
ttenuates P-selectin–mediated endothelial dysfunction and
he myocardial damage resulting from the ischemia-
eperfusion injury (11). Overall, these findings highlight the
entral role of P-selectin in linking inflammatory and
hrombotic pathophysiological pathways at the vessel wall,
aking it a uniquely attractive therapeutic target (9–15).
ELECT-ACS trial: a critical appraisal. In this issue of
he Journal, Tardif et al. (16) present an interesting study
hat sought to assess the value of inclacumab, a novel
-selectin antagonist, to reduce myocardial damage during
CI. In the SELECT-ACS trial, a total of 544 patients
ith NSTEMI were randomly allocated to receive an
nfusion of 5 or 20 mg/kg of inclacumab or placebo (1:1:1)
efore coronary angiography. The primary endpoint, the
ncrease of troponin I levels at 16 and 24 h, was evaluated in
he 322 patients who eventually underwent PCI. In-
lacumab 5 mg/kg had no effect on any efficacy outcome
easure. However, placebo-adjusted geometric mean per-
ent changes in troponin with inclacumab 20 mg/kg were
22.4% at 16 h (p  0.066) and 24.4% at 24 h (p 
.053). In addition, in this group, peak troponin was
educed by 23.8% (p  0.054) and the area under the curve
ver 24 h by 33.9% (p  0.075) compared with placebo.
hese results were paralleled by the corresponding creatine
inase-myocardial band findings (reduction of 16.3%
p  0.088] and 17.4% [p  0.055] at 16 and 24 h,
espectively). Interestingly, the more clinically orientated
ndpoint of a 3-fold increase in creatine kinase-myocardial
and over the upper normal limit, was seen in 8.9% of
atients in the inclacumab group versus 18.3% of patients in
he placebo group (p  0.051). From a pharmacodynamic
tandpoint, the high dose of inclacumab was associated with
significant reduction in soluble P-selectin levels. The study
as largely unpowered to detect differences in major clinical
vents. Notwithstanding the unique statistical problem that
ll different p values addressing drug efficacy were just above
he 0.05 limit (weak statistical certainty), the consistency of
ll efficacy analyses appears encouraging. Overall, the
ELECT-ACS trial findings strongly suggest a potential
linical value of this novel P-selectin inhibiting strategy, and
hus the authors should be commended for this elegant,
lbeit preliminary, trial that expands our knowledge on
lternative therapeutic strategies devised to improve PCI
esults (16). However, several methodological issues emerge
rom the present investigation. iFirst, this is a phase 2 study with the primary endpoint
nalyzed in patients as treated. However, randomized trials
ddressing “clinical efficacy” require intention-to treat anal-
sis. Reassuringly, primary outcome measure estimates were
dentical when all patients were analyzed. Second, patients
andomized but eventually not requiring PCI, were not
valuated for efficacy. Patients with NSTEMI who are
edically managed have been largely underrepresented in
linical trials despite their adverse prognosis (17). More
otent platelet inhibition with ticagrelor, but not prasugrel,
as shown to be associated with better clinical outcomes,
ncluding reduced mortality, compared with clopidogrel in
edically managed patients (18,19). These benefits have
een attributed to properties that go beyond their platelet
2Y12 inhibition known as “off-target” effects (18). Thus,
he antiplatelet and anti-inflammatory effects of the
-selectin antagonist inclacumab might have also benefited
edically managed NSTEMI patients. In this regard, data
n this patient subset would have been of additional value,
specially if consistent with those seen after PCI. Third, the
ime from symptom onset to treatment and the delay
nterval from the start of infusion to PCI were not clarified.
ue to the net efficacy differences among the 2 doses tested
n the study, it remains possible that a longer infusion time
efore PCI would have been associated with more favorable
fficacy outcomes. Likewise, assessing the potential correla-
ion between plasma-soluble P-selectin levels and the
hange in troponin levels would have reinforced causality.
ourth, P-selectin has been classically implicated in the
athogenesis of the neointimal hyperplasia response elicited
y PCI (15). In this regard, a late angiographic evaluation
ould have been of interest to ascertain whether neointimal
roliferation is also affected by the short-term exposure to
his drug in the acute phase of treatment. Interestingly,
eointimal proliferation and strut coverage are closely in-
errelated, and, therefore, additional mechanistic studies
ideally using detailed optical coherence tomography imag-
ng) should be performed to obtain further insights into the
otential effects of this drug on late neointimal proliferation
nd strut coverage (20). Likewise, long-term clinical studies
ssessing the potential effects on clinical restenosis and stent
hrombosis would be also of value. Fifth, although the study
as largely underpowered for major clinical events, the
umerically higher incidence of death or myocardial infarc-
ion during follow-up in the active treatment arms (2 of 175
atients [1.1%] in the placebo group vs. 17 of 355 [4.8%] in
he combined treatment groups [odds ratio: 4.35; 95%
onfidence interval: 1.12 to 16.93]) is of concern and would
equire a close reappraisal for safety in larger future studies.
inally, in this study, the value of the P-selectin antagonist
as evaluated in patients mainly receiving standard clopi-
ogrel therapy. Whether inclacumab efficacy is maintained
n patients receiving the newer, more potent antiplatelet
gents (prasugrel, ticagrelor) and also in patients undergoing
ntensive statin therapy warrants additional investigation.
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between platelets and inflammation. Thus, targeting
P-selectin represents a rational therapeutic strategy to mod-
ulate pivotal components of atherogenesis and its ischemic
complications. The findings of the SELECT-ACS trial
assessing the impact a P-selectin inhibiting strategy with
inclacumab on acute myocardial injury in NSTEMI patients
undergoing PCI are exciting and hold clear clinical promise.
Future studies are warranted to assess whether the changes
in cardiac markers induced by inclacumab indeed reflect
therapeutic efficacy and also whether eventually they may
translate into superior long-term clinical outcomes. Addi-
tional studies are warranted to define other clinical settings
where this strategy may also hold therapeutic potential, such
as in patients undergoing coronary artery bypass graft
surgery. The SELECT-CABG study (NCT01245634) will
indeed be contributory to this extent and will also provide
further insights into the safety and efficacy of this therapeu-
tic option. Reassuringly, better safety and efficacy evidence
will lead to better practice and eventually to better clinical
outcomes.
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